Lilly submits NDA to FDA for oral once-daily baricitinib to treat moderate-to-severe RA
As a result, Incyte will receive a milestone payment of $35m from Lilly related to the NDA submission. If baricitinib is granted U.S. regulatory approval, Incyte will receive